Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hypofractionated radiotherapy for prostate cancer stands the test of time

Key clinical point: Hypofractionated radiotherapy is not inferior to conventional radiotherapy for treating localized prostate cancer.

Major finding: The 8-year rate of freedom from biochemical or clinical failure was 80.6% with 74 Gy/37 fractions and a noninferior 83.7% with 60 Gy/20 fractions (HR, 0.85; P = .11) but a potentially inferior 78.5% with 57 Gy/19 fractions (HR, 1.17; P = .10).

Study details: Update of a phase 3 trial of 3,216 men with node-negative T1b-T3a localized prostate cancer who received conventional vs. hypofractionated high-dose, intensity-modulated radiotherapy (the CHHiP trial).

Disclosures: The trial was funded by Cancer Research UK, Department of Health (UK), and the National Institute for Health Research Cancer Research Network. The presenter disclosed relationships with a range of pharmaceutical companies.


Dearnaley DP et al. GUCS 2020. Abstract 325.